Dumas F, Bougouin W, Perier M C, Marin N, Goulenok C, Vieillard-Baron A, Diehl J L, Legriel S, Deye N, Cronier P, Ricôme S, Chemouni F, Mekontso Dessap A, Beganton F, Marijon E, Jouven X, Empana J P, Cariou A
Emergency Department, Cochin Hospital-APHP, Université Paris Cité, Paris Cardiovascular Research Centre, INSERM U970, Sudden Death Expertise Centre, Paris, France.
Medical Intensive Care Unit, Institut Jacques Cartier, Massy, France.
Resusc Plus. 2023 Aug 31;16:100460. doi: 10.1016/j.resplu.2023.100460. eCollection 2023 Dec.
While the short-term prognosis of cardiac arrest patients - nearly 250,000 new cases per year in Europe - has been extensively studied, less is known regarding the mid and long-term outcome of survivors.
The aim of the DESAC study is to describe mid- and long-term survival rate and functional status of cardiac arrest survivors, and to assess the influence of pre and intra hospital therapeutic strategies on these two outcomes.
Between Jul 2015 and Oct 2018, adult patients over 18 years who were discharged alive from any intensive care units (public and private hospitals) in the Ile-de-France area (Paris and suburbs, France) after a non-traumatic cardiac arrest were screened for participation in this multicentric study. Survivors were included after they signed (or the proxies) an informed consent before discharge during initial hospitalisation. We calculated that including 600 patients in total would allow an 80% power to demonstrate a 2 years survival rate difference of 10% between patients who did and those who did not receive therapeutic hypothermia after resuscitation. Pre- and in-hospital data related to the circumstances surrounding the event and to the therapeutic interventions (such as cardio-pulmonary resuscitation, defibrillation, emergent coronary revascularization, neuroprotective therapeutics) were collected. After discharge, patients were interviewed at 3 months, 6 months and every year thereafter for a minimum follow-up of 26 months and a maximum follow-up of 48 months. Information on vital status, occurrence of cardiovascular events, medications and a comprehensive assessment of the functional status (qualitive of life as assessed by the Short-Form General Health Survey (SF36) scale, activities of daily living (ADL) scale, neurological Cerebral Performance Categories (CPC) and Overall Performance Categories (OPC) scales, socio-professional activities) were collected at follow-up interviews.
The DESAC study should provide important information regarding several dimensions of the mid and long-term prognosis of cardiac arrest survivors and on the benefit (and potentially harm) of early therapeutic strategies.
虽然心脏骤停患者的短期预后——欧洲每年有近25万新发病例——已得到广泛研究,但关于幸存者的中长期结局却知之甚少。
DESAC研究的目的是描述心脏骤停幸存者的中长期生存率和功能状态,并评估院前和院内治疗策略对这两个结局的影响。
在2015年7月至2018年10月期间,对法国巴黎大区(法国巴黎及其郊区)任何重症监护病房(公立和私立医院)非创伤性心脏骤停后存活出院的18岁以上成年患者进行筛查,以参与这项多中心研究。幸存者在首次住院期间出院前签署(或由代理人签署)知情同意书后被纳入研究。我们计算得出,总共纳入600名患者将有80%的把握度证明复苏后接受治疗性低温与未接受治疗性低温的患者之间2年生存率相差10%。收集与事件发生情况和治疗干预措施(如心肺复苏、除颤、急诊冠状动脉血运重建、神经保护治疗)相关的院前和院内数据。出院后,在3个月、6个月及此后每年对患者进行访谈,随访时间最短26个月,最长48个月。在随访访谈中收集有关生命状态、心血管事件发生情况、用药情况以及功能状态的综合评估信息(通过简明健康调查(SF36)量表评估生活质量、日常生活活动(ADL)量表、神经学脑功能分类(CPC)和总体表现分类(OPC)量表、社会职业活动)。
DESAC研究应能提供有关心脏骤停幸存者中长期预后的几个方面以及早期治疗策略的益处(和潜在危害)的重要信息。